Stem Cell and Regenerative Therapy Regulation Advisory Group.
Do you support it?
Want to know if it passes?
We'll email you when AB 617 moves — a committee vote, a floor vote, or a signature. Nothing else.
Free forever · unsubscribe in one click.
Your answer was recorded either way.
Which district are you in?
Your ZIP is all we need to match you to your own representatives — so we can tell you how they voted on AB 617.
You're tracking AB 617
We'll email you the moment it moves.
AB 617 — Stem Cell and Regenerative Therapy Regulation Advisory Group.
Last action — From committee: Filed with the Chief Clerk pursuant to Joint Rule 56.
No card. One bill, free forever — alerts when it moves.
-
✓Introduced
-
2In Committee
-
3Passed Assembly
-
4Passed Senate
-
5To Executive
-
6Enacted
This bill died with 2019-2020 Regular Session. It reached “In Committee” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.
This bill is no longer active — its legislative session has ended, so there is no live prognosis. It would have to be reintroduced in the current session to move again.
Summary
Existing law, including, among other laws, the Medical Practice Act, the Osteopathic Act, and the Nursing Practice Act, provides for the licensure and regulation of various health care practitioners by various boards within the Department of Consumer Affairs, including the Medical Board of California, the Osteopathic Medical Board of California, and the Board of Registered Nursing. Existing law requires licensed health care practitioners who perform stem cell therapies that are subject to regulation by the United States Food and Drug Administration (FDA) , but are not FDA approved, to communicate to their patients specified information regarding the therapies in a notice and in writing prior to providing the initial stem cell therapy. Existing law requires the State Department of Public Health to establish and maintain an anonymous registry of embryos that are available for research. Existing law makes it the policy of the state that research involving the derivation and use of human embryonic stem cells, human embryonic germ cells, and human adult stem cells shall be reviewed by a stem cell research oversight committee. The California Stem Cell Research and Cures Act, an initiative measure approved by the voters at the November 2, 2004, statewide general election as Proposition 71, establishes the California Institute for Regenerative Medicine (CIRM) , the purpose of which is, among other things, to make grants and loans for stem cell research, for research facilities, and for other vital research opportunities to realize therapies, protocols, and medical procedures that will result in the cure for, or substantial mitigation of, diseases and injuries. Existing law prohibits amendment of Proposition 71 by the Legislature unless the amendment is approved by the voters, or the amendment is accomplished by a bill introduced after the first 2 full calendar years and approved by a vote of 70% of both houses, and only if the amendment enhances the ability of the institute to further the purposes of the grant and loan programs. Existing federal law creates an electronic registration and listing system for establishments that manufacture human cells, tissues, and cellular and tissue-based products (HCT/Ps) and establishes current good tissue practice and other procedures to prevent the introduction, transmission, and spread of communicable diseases by HCT/Ps. Existing federal law requires the FDA to register, list, and regulate HCT/Ps for these purposes. This bill would require the Medical Board of California, no later than February 1, 2020, to establish the Stem Cell and Regenerative Therapy Regulation Advisory Group comprised of specified members, including 3 members appointed by the CIRM, as specified. By imposing a duty on the CIRM to appoint members to the Stem Cell and Regenerative Therapy Regulation Advisory Group, the bill would require for passage a 70% vote. The bill, on or after July 1, 2020, would authorize the board to make the appointments that CIRM fails to make. The bill would require the advisory group to convene a series of stakeholder meetings to review the Medical Practice Act, the Osteopathic Act, and the State Department of Public Health's current licensing and certification laws and procedures to determine whether those laws and procedures provide for adequate consumer protection for the use of stem cell therapies in clinics and other practice settings, to make recommendations to the Legislature, on or before July 1, 2020, regarding how to improve state oversight of licensees offering or providing stem cell therapies to patients, and to make recommendations to the board for the adoption of emergency regulations, as specified. The bill would authorize the board to adopt those recommended emergency regulations, as specified. The bill would repeal these provisions on January 1, 2024.
Bill Text
- Amended 05/01/19 - Amended Assembly Current pdf May 01, 2019
- Amended 04/22/19 - Amended Assembly pdf April 22, 2019
- Amended 03/21/19 - Amended Assembly pdf March 21, 2019
- Introduced 02/14/19 - Introduced pdf February 14, 2019
- AB617 View text html
Action History
-
From committee: Filed with the Chief Clerk pursuant to Joint Rule 56.
-
Died pursuant to Art. IV, Sec. 10(c) of the Constitution.
-
In committee: Held under submission.
-
In committee: Set, first hearing. Referred to APPR. suspense file.
-
Re-referred to Com. on APPR.
-
From committee chair, with author's amendments: Amend, and re-refer to Com. on APPR. Read second time and amended.
-
From committee: Do pass and re-refer to Com. on APPR. with recommendation: To Consent Calendar. (Ayes 15. Noes 0.) (April 23). Re-referred to Com. on APPR.
-
Re-referred to Com. on HEALTH.
-
From committee chair, with author's amendments: Amend, and re-refer to Com. on HEALTH. Read second time and amended.
-
Re-referred to Com. on HEALTH.
-
From committee chair, with author's amendments: Amend, and re-refer to Com. on HEALTH. Read second time and amended.
-
Referred to Com. on HEALTH.
-
From printer. May be heard in committee March 17.
-
Read first time. To print.
Sponsors
- Mullin · Primary
Sponsorship breakdown
Export CSV (upgrade) →1 sponsors · 0 co-sponsors · 121 not signed on
Sponsors (1)
- Mullin
Co-sponsors (0)
None.
Not signed on (121)
121 members have not signed on to this bill.
Show all 121 →"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.
Votes
| Party | Yea | Nay | Present | Not Voting |
|---|---|---|---|---|
| Unaffiliated | 9 | 0 | 0 | 0 |
| Democratic | 5 | 0 | 0 | 0 |
| Republican | 1 | 0 | 0 | 0 |
| Total | 15 | 0 | 0 | 0 |
| % of votes cast | 100% | 0% | 0% | 0% |
How each member voted (15)
| Member | Party | Vote |
|---|---|---|
| Burke | — | Yea |
| Wood | — | Yea |
| Rodriguez | — | Yea |
| Santiago | — | Yea |
| Mayes | — | Yea |
| Bigelow | — | Yea |
| McCarty | — | Yea |
| Waldron | — | Yea |
| Nazarian | — | Yea |
| Aguiar-Curry, Cecilia M. | Democratic | Yea |
| Bonta, Mia | Democratic | Yea |
| Carrillo, Juan | Democratic | Yea |
| Limón, Monique | Democratic | Yea |
| Ramos, James C. | Democratic | Yea |
| Flora, Heath | Republican | Yea |
Subjects
Frequently asked questions
- What does AB 617 do?
- Existing law, including, among other laws, the Medical Practice Act, the Osteopathic Act, and the Nursing Practice Act, provides for the licensure and regulation of various health care practitioners by various boards within the Department of Consumer Affairs, including the Medical Board of California, the Osteopathic Medical Board of California, and the Board of Registered Nursing. Existing law requires licensed health care practitioners who perform stem cell therapies that are subject to regulation by the United States Food and Drug Administration (FDA) , but are not FDA approved, to communicate to their patients specified information regarding the therapies in a notice and in writing prior to providing the initial stem cell therapy. Existing law requires the State Department of Public Health to establish and maintain an anonymous registry of embryos that are available for research. Existing law makes it the policy of the state that research involving the derivation and use of human embryonic stem cells, human embryonic germ cells, and human adult stem cells shall be reviewed by a stem cell research oversight committee. The California Stem Cell Research and Cures Act, an initiative measure approved by the voters at the November 2, 2004, statewide general election as Proposition 71, establishes the California Institute for Regenerative Medicine (CIRM) , the purpose of which is, among other things, to make grants and loans for stem cell research, for research facilities, and for other vital research opportunities to realize therapies, protocols, and medical procedures that will result in the cure for, or substantial mitigation of, diseases and injuries. Existing law prohibits amendment of Proposition 71 by the Legislature unless the amendment is approved by the voters, or the amendment is accomplished by a bill introduced after the first 2 full calendar years and approved by a vote of 70% of both houses, and only if the amendment enhances the ability of the institute to further the purposes of the grant and loan programs. Existing federal law creates an electronic registration and listing system for establishments that manufacture human cells, tissues, and cellular and tissue-based products (HCT/Ps) and establishes current good tissue practice and other procedures to prevent the introduction, transmission, and spread of communicable diseases by HCT/Ps. Existing federal law requires the FDA to register, list, and regulate HCT/Ps for these purposes. This bill would require the Medical Board of California, no later than February 1, 2020, to establish the Stem Cell and Regenerative Therapy Regulation Advisory Group comprised of specified members, including 3 members appointed by the CIRM, as specified. By imposing a duty on the CIRM to appoint members to the Stem Cell and Regenerative Therapy Regulation Advisory Group, the bill would require for passage a 70% vote. The bill, on or after July 1, 2020, would authorize the board to make the appointments that CIRM fails to make. The bill would require the advisory group to convene a series of stakeholder meetings to review the Medical Practice Act, the Osteopathic Act, and the State Department of Public Health's current licensing and certification laws and procedures to determine whether those laws and procedures provide for adequate consumer protection for the use of stem cell therapies in clinics and other practice settings, to make recommendations to the Legislature, on or before July 1, 2020, regarding how to improve state oversight of licensees offering or providing stem cell therapies to patients, and to make recommendations to the board for the adoption of emergency regulations, as specified. The bill would authorize the board to adopt those recommended emergency regulations, as specified. The bill would repeal these provisions on January 1, 2024.
- Who sponsors AB 617?
- AB 617 is sponsored by Mullin.
- What is the current status of AB 617?
- This bill died with 2019-2020 Regular Session. It reached “In Committee” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.
- Where can I track AB 617?
- Track AB 617 free on One Click Politics — get push/email alerts when it moves.
Make your voice heard on AB 617
Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.
Stay ahead of AB 617
Last checked for changes 3 months ago · updated continuously
One Click Politics tracks every bill in Congress and all 50 states.
Track this bill →